がん臨床試験ジャーナル

Clinical Presentation and Management of Osteosarcoma

Abstract

Tarik Zine Belhocine*

Osteosarcoma (OS) is the commonest sort of primary solid tumor that develops in bone. Although standard chemotherapy has significantly improved long-term survival over the past few decades, the result for those patients with metastatic or recurrent OS remains dismally poor and, therefore, novel agents and treatment regimens are urgently required. A hypothesis to elucidate the resistance of OS to chemotherapy is that the existence of drug resistant CSCs with progenitor properties that are responsible of tumor relapses and metastasis.